Alkermes Plc (ALKS)

$27.88

-0.16

(-0.57%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $27.68
    $28.86
    $27.88
    downward going graph

    0.74%

    Downside

    Day's Volatility :4.11%

    Upside

    3.4%

    downward going graph
  • $22.01
    $32.88
    $27.88
    downward going graph

    21.05%

    Downside

    52 Weeks Volatility :33.06%

    Upside

    15.21%

    downward going graph

Returns

PeriodAlkermes PlcSector (Health Care)Index (Russel 2000)
3 Months
13.61%
6.5%
0.0%
6 Months
1.08%
7.1%
0.0%
1 Year
-6.69%
9.8%
0.0%
3 Years
15.06%
14.2%
-20.2%

Highlights

Market Capitalization
4.4B
Book Value
$7.2
Earnings Per Share (EPS)
3.36
PE Ratio
7.89
PEG Ratio
-1057.29
Wall Street Target Price
34.67
Profit Margin
25.17%
Operating Margin TTM
12.36%
Return On Assets TTM
14.65%
Return On Equity TTM
50.45%
Revenue TTM
1.7B
Revenue Per Share TTM
10.34
Quarterly Revenue Growth YOY
21.8%
Gross Profit TTM
893.7M
EBITDA
538.7M
Diluted Eps TTM
3.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
2.67
EPS Estimate Next Year
2.6
EPS Estimate Current Quarter
0.58
EPS Estimate Next Quarter
0.74

Analyst Recommendation

Buy
    63%Buy
    31%Hold
    5%Sell
Based on 19 Wall street analysts offering stock ratings for Alkermes Plc(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
6
6
7
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 24.35%

Current $27.88
Target $34.67

Company Financials

FY18Y/Y Change
Revenue
1.1B
↑ 21.13%
Net Income
-139.3M
↓ 11.8%
Net Profit Margin
-12.73%
↑ 4.75%
FY19Y/Y Change
Revenue
1.2B
↑ 7.01%
Net Income
-196.6M
↑ 41.14%
Net Profit Margin
-16.79%
↓ 4.06%
FY20Y/Y Change
Revenue
1.0B
↓ 11.29%
Net Income
-110.9M
↓ 43.62%
Net Profit Margin
-10.67%
↑ 6.12%
FY21Y/Y Change
Revenue
1.2B
↑ 13.0%
Net Income
-48.2M
↓ 56.55%
Net Profit Margin
-4.1%
↑ 6.57%
FY22Y/Y Change
Revenue
1.1B
↓ 5.28%
Net Income
-158.3M
↑ 228.57%
Net Profit Margin
-14.24%
↓ 10.14%
FY23Y/Y Change
Revenue
1.7B
↑ 49.61%
Net Income
355.8M
↓ 324.78%
Net Profit Margin
21.39%
↑ 35.63%
Q4 FY22Q/Q Change
Revenue
304.7M
↑ 20.73%
Net Income
-28.3M
↓ 55.84%
Net Profit Margin
-9.27%
↑ 16.08%
Q1 FY23Q/Q Change
Revenue
287.6M
↓ 5.61%
Net Income
-41.8M
↑ 48.1%
Net Profit Margin
-14.55%
↓ 5.28%
Q2 FY23Q/Q Change
Revenue
617.4M
↑ 114.68%
Net Income
237.1M
↓ 666.53%
Net Profit Margin
38.4%
↑ 52.95%
Q3 FY23Q/Q Change
Revenue
380.9M
↓ 38.3%
Net Income
47.8M
↓ 79.85%
Net Profit Margin
12.54%
↓ 25.86%
Q4 FY23Q/Q Change
Revenue
377.5M
↓ 0.91%
Net Income
112.8M
↑ 136.15%
Net Profit Margin
29.88%
↑ 17.34%
Q1 FY24Q/Q Change
Revenue
350.4M
↓ 7.18%
Net Income
36.8M
↓ 67.34%
Net Profit Margin
10.51%
↓ 19.37%
FY18Y/Y Change
Total Assets
1.8B
↑ 1.55%
Total Liabilities
653.7M
↑ 9.98%
FY19Y/Y Change
Total Assets
1.8B
↓ 1.07%
Total Liabilities
720.0M
↑ 10.13%
FY20Y/Y Change
Total Assets
1.9B
↑ 7.99%
Total Liabilities
882.7M
↑ 22.61%
FY21Y/Y Change
Total Assets
2.0B
↑ 3.83%
Total Liabilities
911.9M
↑ 3.3%
FY22Y/Y Change
Total Assets
2.0B
↓ 2.99%
Total Liabilities
920.2M
↑ 0.91%
FY23Y/Y Change
Total Assets
2.1B
↑ 8.77%
Total Liabilities
933.5M
↑ 1.45%
Q4 FY22Q/Q Change
Total Assets
2.0B
↑ 1.14%
Total Liabilities
920.2M
↑ 2.36%
Q1 FY23Q/Q Change
Total Assets
1.9B
↓ 2.1%
Total Liabilities
917.2M
↓ 0.33%
Q2 FY23Q/Q Change
Total Assets
2.2B
↑ 13.75%
Total Liabilities
906.7M
↓ 1.13%
Q3 FY23Q/Q Change
Total Assets
2.3B
↑ 4.21%
Total Liabilities
923.6M
↑ 1.86%
Q4 FY23Q/Q Change
Total Assets
2.1B
↓ 6.27%
Total Liabilities
933.5M
↑ 1.07%
Q1 FY24Q/Q Change
Total Assets
2.1B
↓ 0.58%
Total Liabilities
869.1M
↓ 6.9%
FY18Y/Y Change
Operating Cash Flow
99.3M
↑ 417.36%
Investing Cash Flow
-22.2M
↑ 20.91%
Financing Cash Flow
-1.6M
↓ 139.67%
FY19Y/Y Change
Operating Cash Flow
72.1M
↓ 27.4%
Investing Cash Flow
-141.8M
↑ 539.03%
Financing Cash Flow
6.8M
↓ 517.59%
FY20Y/Y Change
Operating Cash Flow
82.8M
↑ 14.94%
Investing Cash Flow
-11.5M
↓ 91.91%
Financing Cash Flow
-2.2M
↓ 132.09%
FY21Y/Y Change
Operating Cash Flow
101.7M
↑ 22.78%
Investing Cash Flow
-66.2M
↑ 476.64%
Financing Cash Flow
29.1M
↓ 1439.11%
FY22Y/Y Change
Operating Cash Flow
21.0M
↓ 79.31%
Investing Cash Flow
-64.5M
↓ 2.51%
Financing Cash Flow
-1.6M
↓ 105.41%
Q4 FY22Q/Q Change
Operating Cash Flow
1.0M
↑ 67.52%
Investing Cash Flow
27.7M
↑ 211.76%
Financing Cash Flow
-271.0K
↑ 27.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-21.3M
↓ 2134.57%
Investing Cash Flow
72.9M
↑ 162.62%
Financing Cash Flow
-22.6M
↑ 8246.86%
Q2 FY23Q/Q Change
Operating Cash Flow
215.7M
↓ 1112.63%
Investing Cash Flow
-119.4M
↓ 263.84%
Financing Cash Flow
7.8M
↓ 134.64%
Q3 FY23Q/Q Change
Operating Cash Flow
99.7M
↓ 53.78%
Investing Cash Flow
-119.4M
↑ 0.0%
Financing Cash Flow
1.6M
↓ 80.0%

Technicals Summary

Sell

Neutral

Buy

Alkermes Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alkermes Plc
Alkermes Plc
14.12%
1.08%
-6.69%
15.06%
36.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alkermes Plc
Alkermes Plc
7.89
7.89
-1057.29
2.67
0.5
0.15
NA
7.2
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alkermes Plc
Alkermes Plc
Buy
$4.4B
36.38%
7.89
25.17%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Alkermes Plc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 617.39M → 350.37M (in $), with an average decrease of 15.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 112.77M → 36.82M (in $), with an average decrease of 67.3% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 52.2%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 37.5%

Institutional Holdings

  • BlackRock Inc

    17.24%

  • Vanguard Group Inc

    11.91%

  • Wellington Management Company LLP

    8.80%

  • State Street Corporation

    5.32%

  • T. Rowe Price Associates, Inc.

    4.92%

  • RTW INVESTMENTS, LLC

    3.58%

Company Information

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Organization
Alkermes Plc
Employees
2100
CEO
Mr. Richard F. Pops
Industry
Health Technology

Discover More

FAQs